ArticleCancers2022

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.

Julie E Bauman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.